Clinical Trial

A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers

Study acronym: VEEV
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 28, 2025 (before its estimated February 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the study is to evaluate the safety and immunogenicity of a novel Venezuelan Equine Encephalitis virus (VEEV) vaccine (V4020) for the first time in humans compared to placebo when administered by subcutaneous or intramuscular injection.
Trial Details
NCT Number NCT07088822
Lead Sponsor Medigen, Inc.
Conditions Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection
Enrollment 39 participants
Start Date 2025-08-15
Primary Completion 2026-02-28 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-28